-
公开(公告)号：US12103964B2
公开(公告)日：2024-10-01
申请号：US17056384
申请日：2019-05-17
IPC分类号： C07K16/00 , A61K39/395 , A61K49/00 , C07K16/14 , C07K16/16 , C07K16/18 , C12N5/0781 , G01N33/50 , G01N33/569
CPC分类号： C07K16/18 , A61K39/39575 , A61K49/0004 , C07K16/14 , C07K16/16 , C12N5/0635 , G01N33/5052 , G01N33/56961 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/92
摘要： In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.
-
公开(公告)号：US20240218328A1
公开(公告)日：2024-07-04
申请号：US18557367
申请日：2022-04-29
IPC分类号： C12N5/0781
CPC分类号： C12N5/0635 , C12N2500/90 , C12N2501/125 , C12N2501/145 , C12N2501/2302 , C12N2501/2303 , C12N2501/2304 , C12N2501/2306 , C12N2501/2307 , C12N2501/231 , C12N2501/2321 , C12N2501/26 , C12N2501/52 , C12N2506/11 , C12N2506/45
摘要： Disclosed are media, kits and methods for the directed differentiation of cells to the B cell lineage. The disclosed differentiation approaches may take primary cells or pluripotent stem cell-derived cells through one or more intermediate cell populations to yield the B lineage cells, using one or more stage-specific media formulations. Thus, media and supplements for carrying out directed differentiation workflows may be comprised in a kit that contains one or more basal media and one or more supplements to be added thereto.
-
公开(公告)号：US12024548B2
公开(公告)日：2024-07-02
申请号：US16244909
申请日：2019-01-10
IPC分类号： C12N15/85 , C07K16/00 , C12N5/0781 , C12N15/10 , C12P21/02
CPC分类号： C07K16/00 , C12N5/0635 , C12N15/1086 , C12N15/85 , C12P21/02 , C07K2317/14 , C07K2317/56 , C12N2510/02 , C12N15/1086 , C12Q2521/507 , C12Q2537/143
摘要： In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformed E. coli cells.
-
4.发明公开公开(公告)号：US20240181054A1
公开(公告)日：2024-06-06
申请号：US18550205
申请日：2022-03-14
申请人： Synthego Corporation
发明人： Robert DEANS , Travis MAURES , Yueting ZHENG , Jared Carlson STEVERMER , Monique DAO , Phillip BALZANO , Rebecca NUGENT
CPC分类号： A61K39/4622 , A61K39/4612 , A61K39/4634 , A61K39/464491 , C07K14/70539 , C12N5/0635 , C12N9/22 , C12N15/11 , C12N15/907 , C07K2319/40 , C12N2310/20 , C12N2510/00 , C12N2800/80
摘要： The application relates to biological components, methods, systems, and kits for modulating immune responses. The disclosed biological components include genetically modified cells comprising an inserted exogenous sequence in a major histocompatibility complex (MHC)-associated gene. The inserted exogenous sequence encodes a peptide and the genetically modified cells express a fusion protein comprising the peptide and at least a portion of the polypeptide encoded by the MHC-associated gene to form a modified MHC complex. The genetically modified cells may present the peptide as an antigen associated with the MHC complex and may be utilized in methods for modulating T cell activity, inducing an immune response, and inducing a tolerogenic response. As such, the disclosed biological components, methods, systems, and kits may be utilized in order to treat and/or prevent a disease or disorder in a subject in need thereof and to screen and validate clinically relevant antigens.
-
公开(公告)号：US11993646B2
公开(公告)日：2024-05-28
申请号：US16994837
申请日：2020-08-17
IPC分类号： C12N5/10 , A61K39/00 , C07K16/00 , C07K16/10 , C07K16/12 , C07K16/18 , C07K16/30 , C07K16/44 , C12N5/0781 , G01N33/68
CPC分类号： C07K16/18 , A61K39/00 , C07K16/00 , C07K16/1018 , C07K16/109 , C07K16/1271 , C07K16/3069 , C07K16/44 , C12N5/0635 , G01N33/6854 , A61K2039/505 , A61K2039/5156 , C07K2317/14 , C07K2317/33 , C07K2317/76 , C12N2510/00
摘要： Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
-
公开(公告)号：US11913023B2
公开(公告)日：2024-02-27
申请号：US17465759
申请日：2021-09-02
发明人： Kathleen Boyle , Hangil Park , Srinivas Kothakota , Mark Selby , Thomas Brennan , Lewis T. Williams
IPC分类号： C12N5/0781 , A61K35/17 , C07K16/30
CPC分类号： C12N5/0635 , A61K35/17 , C07K16/303 , C07K16/3069 , C07K2317/53 , C07K2317/622 , C07K2319/03 , C12N2510/00
摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
-
公开(公告)号：US11865536B2
公开(公告)日：2024-01-09
申请号：US17730615
申请日：2022-04-27
发明人： Girija Goyal , Donald E. Ingber
IPC分类号： B01L3/00 , C12N5/0781 , C12N5/0783 , A61K35/28 , A61P35/00 , A61K35/17 , C12M3/06 , A61P37/04 , C12M3/00 , A61P7/00 , C12N5/00 , C12N5/0786 , C12N5/078 , C12N5/071 , C12N5/09 , G01N33/50
CPC分类号： B01L3/5027 , A61K35/17 , A61K35/28 , A61P7/00 , A61P35/00 , A61P37/04 , C12M21/08 , C12M23/16 , C12N5/0018 , C12N5/069 , C12N5/0635 , C12N5/0636 , C12N5/0645 , C12N5/0651 , C12N5/0693 , G01N33/5011 , B01L2300/0861 , C12N2531/00 , C12N2533/52 , C12N2533/54 , C12N2533/90
摘要： An organ-on-a-chip microfluidic device is disclosed that mimics a human lymph node and/or human lymphoid tissue. The device can include cells from human blood and lymphatic tissue, include an extracellular matrix for the development of immune system components, and provide for the perfusion of fluids and solids resembling blood and lymphatic fluid within micrometer sized channels.
-
公开(公告)号：US20240002794A1
公开(公告)日：2024-01-04
申请号：US18345891
申请日：2023-06-30
发明人： Sonja Offner , Friederike Jung
IPC分类号： C12N5/0781
CPC分类号： C12N5/0635 , C12N2502/30 , C12N2525/00 , C12N2502/1185 , C12N2510/02 , C12N2501/2301 , C12N2501/2302 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2321 , C12N2501/25
摘要： Herein is reported a method for co-cultivating one or more B-cells comprising the step of incubating the one or more B-cells with EL4-B5 cells, whereby the EL4-B5 cells have been obtained/are from a cultivation of EL4-B5 cells that has a cell density of from 600,000 cells/ml up to 1,500,000 cells/ml.
-
公开(公告)号：US20240002793A1
公开(公告)日：2024-01-04
申请号：US18314778
申请日：2023-05-09
发明人： Kathleen Boyle , Hangil Park , Srinivas Kothakota , Mark Selby , Thomas Brennan , Lewis T. Williams
IPC分类号： C12N5/0781 , A61K35/17 , C07K16/30
CPC分类号： C12N5/0635 , A61K35/17 , C07K16/303 , C07K16/3069 , C07K2317/53 , C07K2319/03 , C12N2510/00 , C07K2317/622
摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
-
10.发明公开公开(公告)号：US20230414659A1
公开(公告)日：2023-12-28
申请号：US18034865
申请日：2021-10-29
申请人： Immusoft Corporation
发明人： Christiane S. HAMPE
IPC分类号： A61K35/17 , C12N5/0781 , C12N9/24 , A61P3/00 , A61K9/00
CPC分类号： A61K35/17 , C12N5/0635 , C12N9/2402 , C12Y302/01075 , A61P3/00 , A61K9/0085 , C12N2510/00
摘要： Provided herein are methods for administering engineered B cells to produce a therapeutic agent in vivo. In various embodiments, engineered B cells are directly administered to the central nervous system (CNS). The compositions and methods disclosed herein may be used for enzyme replacement therapy, for example, treatment of diseases or disorders associated with lysosomal storage dysfunction through production of iduronidase (IDUA).
-
-
-
-
-
-
-
-
-
搜索结果
536 条记录 (耗时 0.027 秒)
